In Vivo Podcasts

Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization

Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based biotech is positioning its viral vector platform in this evolving landscape. They discuss NOUS‑209, an off‑the‑shelf neoantigen vaccine for MSI‑H/dMMR tumors and cancer interception in Lynch syndrome, the company’s personalized program NOUS‑PEV, and what it will take—scientifically, operationally, and commercially—for next‑generation cancer vaccines to succeed.

Strategic Intent: Evolving Requirements Of Life Sciences Leadership

In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.

Proof Of Concept: How A Charity Bridges Lab And Clinic

Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features Phil Masterson and Neil Jones, who run its ventures and drug discovery arms, unpacking why charities are increasingly bridging the gap between a promising result in the lab and a medicine in the clinic. Drug discovery, oncology, cancer research, R&D, venture capital, early-stage investment

Strategic Intent: Beyond The Breakthrough - From Approval To Adoption

A medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has spent more than 25 years bringing first-of-their-kind procedural technologies to market. Their conversation digs into medtech's hardest problem — not inventing a technology, but getting physicians to switch and payers to cover it. Using Baird's effort to introduce microwave ablation for thyroid nodules, a minimally invasive alternative to surgery, into the U.S., Mark unpacks how to build a payer strategy early, earn the backing of medical societies, train physicians for genuine adoption, and sidestep the market traps that have sunk countless promising devices. His parting advice for founders who are winning abroad but stuck at the U.S. starting line: do your homework on the market before you spend on the science.

ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany

A landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare journeys. ZS’ Jon Roffman and Bhargav Mantha set the scene.

Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends

a videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe

Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment

One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.

In Vivo Trailer

Strategic Intent: The Rise Of Mid-Cap Dealmakers

Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies

On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices, and explains how Annexon is building two dedicated commercial teams to support both launches. The conversation also covers Annexon’s oral complement inhibitor ANX1502, capital allocation priorities across late-stage and platform programs, and how most-favored-nation (MFN) pricing dynamics are influencing launch sequencing and ex‑US partnering plans.

Proof of Concept - AI in Drug Discovery

In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them. We cover how simulation is used to find and de-risk drug targets, why some AI tools get adopted while others stall, the translational gap between lab results and real patients, and the honest question of where the field is overhyped — and what would count as real proof.

How ElevateBio Is Betting On Every Gene Editing Modality At Once

On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks through ElevateBio's full editing stack: AI-designed large serine recombinases, retrotransposon-based insertion, generative AI-optimized base editors, and an LNP delivery platform that has now shown re-dosing and therapeutically meaningful editing in non-human primates. She also makes the case for epigenetic editing as a potentially underappreciated modality, one that could compete with small molecules in indications where you want potency and specificity without permanently rewriting the genome. And she explains why ElevateBio, with six consecutive years of revenue growth and a 98% manufacturing batch success rate, sees its end-to-end CDMO model as uniquely positioned to turn those tools into medicines partners can actually bring to the clinic.

Tonix’s Bet On Monoclonal Prevention Of Lyme Disease

Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly. In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a fully human monoclonal antibody targeting OspA on the Lyme-causing bacterium Borrelia burgdorferi. Lederman explains why the unusual biology of OspA makes it better suited to a monoclonal approach than a traditional vaccine, how the antibody works inside the tick's midgut to kill the bacteria and block their migration before they can enter a human host, and what the Phase I data tell us about safety, dosing, and the planned two-dose seasonal regimen. He also discusses the adaptive Phase II field study Tonix is preparing for 2027, the lessons (and the lack of information) from the Valor trial, and the long-term questions around who would use this product, how it would be reimbursed, and whether the health economic case can be made for a seasonal preventive in a disease whose chronic form remains medically and politically contested.

The Yescarta Launch Examined

This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers. Here are some of Harris Kaplan’s contributed articles for In Vivo: Commercialization 3.0: Achieving New Product Success In Health Care’s New Era Commercialization 3.0: Recognizing And Managing The Human Side Of Change Physician Behavioral Inertia: Innovation’s Greatest Enemy

Philips' Shez Partovi on increasing AI adoption, clinicians' attitudes and the hybrid care model

AI, Philips, Healthtech, Future Health Index 2026

GATC Health’s Derisq AI, A FICO Score for Drug Development

GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back.

Jeremy Levin’s Call to Action to Save American Biotech

A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-term capital structures mismatched to drug development timelines, eroding public trust in science and vaccines, and the hollowing out of NIH, FDA, and CDC. He outlines what bold leadership looks like in practice — defending facts, engaging patients, and treating biotech as national infrastructure before it's too late.

Decoding Cell Stress at Soley Therapeutics

Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

Kurma’s €215m Fund And What It Says About European Funding Environment

Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment

Podcast: Inside Arcutis with CEO Frank Watanabe

Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation. #biotech #dermatology #immunodermatology #pharma #drugdevelopment #leadership